Funding news
Zumutor Biologics logo

Zumutor Biologics Raises $7.3

Recently funded · $7.3M Series bHospitals and Health CareUSView source

Get the full Zumutor Biologics company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The race to develop new cancer therapies just got a boost for Zumutor Biologics, which announced it has secured $7.3M in Series B funding. The capital will support the company's mission to advance novel immuno-oncology therapeutics, particularly its lead asset, ZM008.

Zumutor Biologics focuses on treatments that drive transformational improvements in cancer care through NK cell engagement. Its lead candidate, ZM008, is a first-in-class antibody designed to activate NK cells by blocking inhibitory signals. The company is on track for an IND filing by Q2 2022, with Phase 1 clinical trials to follow. Headquartered in Cambridge, MA, Zumutor also conducts R&D at its ISO certified lab in Bangalore, India.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
Terran Orbital Corporation logo

Terran Orbital Corporation

United States

$37.1M
2
Heroku logo

Heroku

United States

$10.0M
3
Snowplow logo

Snowplow

United Kingdom

$40.0M
4
Tomo Mortgage logo

Tomo Mortgage

United States

$20.0M
5
Leaf Agriculture logo

Leaf Agriculture

United States

$17.4M